RayKnowChina Research Map
Shortlist0

RecruitingAmyotrophic lateral sclerosisPhase 1

Registered title, quoted from ClinicalTrials.gov

The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor Cells (XS228CN) in Subjects With Amyotrophic Lateral Sclerosis

An open trial on amyotrophic lateral sclerosis, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 13 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07118319, read on 13 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Those who have had a malignant tumor within 5 years prior to screening or are undergoing antitumor therapy;

    Exclusion criterion 18

  3. Active hepatitis B, active hepatitis C, human immunodeficiency virus (HIV) antibody or treponema pallidum antibody positive at screening;

    Exclusion criterion 15

  4. Patients with birth-potential (both male and female) must agree to use effective non-drug contraceptive measures from the time of signing the informed consent until 6 months after the conclusion of the trial;

    Inclusion criterion 4

    Pregnant or breastfeeding women;

    Exclusion criterion 20

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07118319, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • 18-75 years of age (inclusive of 18 and 75 years), regardless of gender;
  • Diagnosed of definite or probable ALS according to the revised EI Escorial criteria;
  • Respiratory function FVC at baseline was ≥70% of the predicted value (FVC%);
  • Patients with birth-potential (both male and female) must agree to use effective non-drug contraceptive measures from the time of signing the informed consent until 6 months after the conclusion of the trial;
  • Volunteer to participate in the clinical study, understand and sign the informed consent form.

Exclusion Criteria:

  • Subject has signs and symptoms of neuromuscular weakness, and other causes of muscle weakness cannot be ruled out;
  • Baseline body mass index (BMI) < 18.5 kg/m²;
  • Primary lateral sclerosis presenting only with upper motor neuron symptoms;
  • Significant psychiatric disorders that the investigator assesses may affect evaluation;
  • Diseases causing neurological or muscular dysfunction, such as metabolic muscle diseases or myasthenia gravis;
  • Diagnosed autoimmune diseases with uncontrolled severe arthritis or other conditions (e.g., lameness) that the investigator assesses may affect evaluation;
  • Acute active infections requiring antibiotics, antivirals, or antifungals that occurred within the 2 weeks prior to screening and are not controlled;
  • Subject diagnosed with active pulmonary tuberculosis or treated for suspected tuberculosis;
  • Diagnosed severe pulmonary diseases that the investigator assesses may affect evaluation;
  • Poorly controlled hypertension;
  • Previous or detected cardiac abnormalities;
  • A history of cirrhosis, chronic hepatitis, or liver function at screening;
  • A history of chronic kidney disease;
  • Previous history of bleeding, abnormal clotting, or being treated with anticoagulation;
  • Active hepatitis B, active hepatitis C, human immunodeficiency virus (HIV) antibody or treponema pallidum antibody positive at screening;
  • History of severe trauma or surgery and may affect the assessment judged by investigator;
  • Subjects with contraindications to lumbar puncture, including menifestations of injection site infection or high intracranial pressure.
  • Those who have had a malignant tumor within 5 years prior to screening or are undergoing antitumor therapy;
  • Have participated in other clinical trials within 3 months prior to screening;
  • Pregnant or breastfeeding women;
  • Subject who is judged by the investigator to be unsuitable for the clinical trial.

Quoted from ClinicalTrials.gov, NCT07118319, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07118319, read on 13 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07118319